Kinase Cell-Based Assays for Selectivity Assessment and Personalized Medicine
|
|
- Eustacia Lucas
- 5 years ago
- Views:
Transcription
1 Kinase Cell-Based Assays for Selectivity Assessment and Personalized Medicine Deborah J. Moshinsky, PhD January 16, 13 Cell Assay Innovations, Inc. 1
2 Outline of Presentation Focus on Cellular Assays More Physiologically Relevant Results Pim kinase drug discovery program - cellular assays for selectivity and lead optimization Personalized medicine - utilizing cellular assays to combat drug resistance - functional investigation of mutant kinases - guiding patient treatment options 2
3 Outline of Presentation Focus on Cellular Assays More Physiologically Relevant Results Pim kinase drug discovery program - cellular assays for selectivity and lead optimization Personalized medicine - utilizing cellular assays to combat drug resistance - functional investigation of mutant kinases - guiding patient treatment options 3
4 Cancer Drug Resistance eg. Imatinib Imatinib (Gleevec, Novartis) approved in 1 for Chronic Myeloid Leukemia (CML) inhibitor of Abl kinase (BCR-Abl) revolutionized treatment of CML -3% of patients develop resistance frequently caused by mutation of Abl to prevent inhibitor binding over 3 point mutations documented in patient samples T315I gatekeeper mutation common X wild type kinase drug resistant mutant kinase 4
5 A Strategy to Combat Drug Resistance Screen inhibitors against wild-type and mutant forms of kinase Successfully utilized by Ariad inhibitors against wild type Abl, [T315I], and others development of Ponatinib approved in Dec 12 (Iclusig ) inhibits wt, [T315I] and other mutant forms of Abl wild type kinase imatinib resistant mutant kinase 5
6 ClariCELL Platform for Drug-Resistant Mutants Expression Vector for Kinase Abl or Abl [T315I] or Abl [E255V] TMB Transfection HRP HRP ptyr HEK293 (or other) Compounds Lyse ELISA assay (or comparable) incubate transfer 6
7 Abl Autophosphorylation Cellular Assays Abl autophosphorylation Abl1 wild type Abl1 [T315I] Abl E255V] Negative Control P Abl wt P P Abl [T315I] Abl [E255V] kinase dead Abl Quantify autophosphorylation and measure modulation by kinase inhibitors. Screen for more effective compounds early in the drug discovery process activity against wild type and mutant targets 7
8 Abl Cellular Data - Validation Imatinib Ponatinib wt Abl -.3uM Abl [T315I] >1uM Abl [E255V] >1uM [cmpd] M 1 8 wt Abl -.1uM Abl [T315I] -.56uM Abl [E255V] -.5uM [cmpd] M Imatinib only inhibits wt form of Abl Ponatinib inhibits wt and both mutant Abl forms Correlation with clinical activity 8
9 1 Abl Cellular Data - Validation 8 wt Abl Abl [E255V] [cmpd] M 1 8 dasatinib ~.6uM imatinib -.3uM ponatinib -.1uM ref inhib 1 >6uM [cmpd] M dasatinib ~.6uM imatinib -.3uM 1 ponatinib -.1uM 8 ref inhib 1 >6uM Abl [T315I] dasatinib >1uM imatinib >1uM ponatinib -.56uM ref inhib 1 >6uM [cmpd] M dasatinib ~.1uM imatinib >1uM ponatinib -.5uM ref inhib 1 >6uM [cmpd] M 9
10 Correlation of Cellular Data with Clinical Imatinib Dasatinib Ponatinib Abl wild type IC5 (µm) Clinical Activity vs. Abl wild type Yes Yes Yes Abl [E255V] IC5 (µm) >1.1.5 Clinical Activity vs. Abl [E255V] No Yes Yes Abl [T315I] IC5 (µm) >1 >1.6 Clinical Activity vs. Abl [T315I] No No Yes General overall correlation Compounds generating IC5 in cellular assay are active in clinic. 1
11 No Cellular Activity with Reference Compound Assay Biochemical IC5 at Km ATP Biochemical IC5 at 1mM ATP Biochemical IC5 Differen<al Cellular IC5 (um) Wt Abl1 75nM 13nM 17- fold >6 Abl1 E255K 1nM 45nM 32- fold >6 Abl1 T315I 6.4nM 89nM 139- fold >6 Inhibition of Abl and mutants is sensitive to ATP concentration Cell-based potency and selectivity determinations are important! 11
12 Benefits of ClariCELL Platform Functional activity of kinase measured in a physiologically relevant setting Ser/Thr as well as Tyr kinase targets Full length kinases Human cell system Quick turnaround time for assay develoment 3-4 weeks Multiplexing capability Seed Measure Treat Lyse 12
13 Increasing Efficiency with Multiplexing traditional paradigm multiplexed paradigm stauro1 stauro2 8 8 IC5=.uM stauro2 8 8 IC5=.uM IC5=.69uM stauro stauro1 8 LOGEC5 EC LOGEC5 stauro2 EC5 stauro LOGEC staurosporine EC Result LOGEC5 EC cell-based assays IC5=.69uM LOGEC5 EC results for 3 targets in 1 assay LOGEC5 EC5 13. LOGEC5 EC LOGEC5 EC IC5 = 9.8uM Result 3 IC5=14uM 1. Result log[cmpd]um log[cmpd]um IC5=14uM 71.6 LOGEC SGI EC IC5 =.43uM LOGEC5 EC LOGEC staurosporine EC5.1 8 IC5 = 9.8uM LOGEC5 EC LOGEC5 EC5 -.5 Result 3 IC5=14uM 1. log[cmpd]um log[cmpd]um IC5=14uM 71.6 LOGEC SGI EC LOGEC5 EC5 8 IC5 =.43uM IC5=.uM. IC5=.69uM -.5 Result IC5=.uM.5. Result 1 LOGEC5 stauro2 EC5 -.5 IC5=.69uM
14 Functional Analysis of Mutant Kinases Cellular assay system useful for biological insight pathway alterations resulting from mutant kinase proteomic analysis of cell lines expressing wt vs. mutant kinases eg. RPPA analysis to map pathway alterations Working with Carna Biosciences to map mutant cell lines Characterization of known or newly discovered mutations 14
15 Guiding Physician Treatment Options Cellular system generally correlates with clinical response to inhibitors over-simplified system Utilize systems biology to model in vivo parameters in vivo drug exposure pharmacodynamics protein binding Cellular Assay Results drug influx/efflux ADME properties Model useful to guide treatment options which patients should respond best to which kinase inhibitor. 15
16 Beyond Imatinib and Abl Numerous examples of kinase inhibitor drug resistance Abl, Abl [T315I] EGFR, EGFR [T79M] Flt3, Flt3 [G697R] PDGFRa, PDGFRa [T674I] Kit, Kit [T67I] Alk, Alk [L1196M] Mutant kinases in other disease areas LRRK2, LRRK2 [G19S], others Parkinson s disease Systematically develop assays for clinically relevant mutant kinases Partners for drug discovery, functional analysis, and treatment options 16
17 Summary Mechanism-based cellular assays are important tools for selectivity assessment enabled Pim kinase project selectivity could not be predicted from biochemical results ClariCELL assays are valuable tools for personalized medicine drug discovery compounds that inhibit wt and mutant forms of kinases address cancer drug resistance functional characterization of mutations modeling to guide physician treatment options 17
5.36 Biochemistry Laboratory Spring 2009
MIT OpenCourseWare http://ocw.mit.edu 5.36 Biochemistry Laboratory Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Laboratory Manual for URIECA
More informationSimplifying Kinase Profiling Using ADP Detection with the Transcreener Kinase Assay Introduction Figure 1. Transcreener Kinase Assay Principle
Simplifying Kinase Profiling Using ADP Detection with the Transcreener Kinase Assay Karen M. Kleman-Leyer, Tony A. Klink, Thane A. Westermeyer and Robert G. Lowery Introduction A variety of HTS kinase
More informationQS S Assist TK_ELISA Kit
QS S Assist TK_ELISA Kit Description TK ELISA Kit is designed for use in pharmacological assays for TK that detects phosphorylated substrate with horseradish peroxidase (HRP)-conjugated anti-phosphotyrosine
More informationMaximize reproducibility of your biological sample prep
pipette automation Maximize reproducibility of your biological sample prep qpcr PCR ELISA Kinase assays Cell based assays NGS library preparation Protein assays Custom LH Enzymatic reactions How can PIPETMAX
More informationQS S Assist STK_FP Kit
QS S Assist STK_FP Kit Description STK FP kit is designed for use in pharmacological assays for STK based on fluorescence polarization. The kit includes assay buffer, human protein kinase, ATP/fluorescence-
More informationIn Vitro Pharmacology Services
In Vitro Pharmacology Services Simplify Your Drug Discovery Workflow What s What s Inside: Inside: Why DiscoverX Services x GPCR Screening & Profiling x Kinase Screening & Profiling x Safety Screening
More informationAdvanced Lead Optimization Efforts Through Innovative and Comprehensive GPCR and Kinase Panels
Advanced Lead Optimization Efforts Through Innovative and Comprehensive GPCR and Kinase Panels Elizabeth R. Quinn, Ph.D. and Daniel Jones [subhead] Use of industry leading GPCR and kinase panels to gain
More informationSupplementary Information
Supplementary Information Supplementary Figures Supplementary Figure 1. MLK1-4 phosphorylate MEK in the presence of RAF inhibitors. (a) H157 cells were transiently transfected with Flag- or HA-tagged MLK1-4
More informationTARGET VALIDATION. Maaike Everts, PhD (with slides from Dr. Suto)
TARGET VALIDATION Maaike Everts, PhD (with slides from Dr. Suto) Drug Discovery & Development Source: http://dlab.cl/molecular-design/drug-discovery-phases/ How do you identify a target? Target: the naturally
More informationDiscovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology
20131009-03 Discovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology James Hendrix, Ph.D. President - Technology Med Chem &
More informationProfiling Ligands Of GPCR Targets Using An Optical Biosensor With Dynamic Mass Redistribution Technology
Profiling Ligands Of GPCR Targets Using An Optical Biosensor With Dynamic Mass Redistribution Technology Paul Lee, Ph.D. Lead Discovery Amgen Inc. Thousand Oaks, CA 2008 Label-Free Summit, Corning NY October
More informationDevelopment of an AlphaLISA MEK1 Kinase Assay Using Full-Length ERK2 Substrate
TECHNICAL NOTE Development of an AlphaLISA MEK1 Kinase Assay Using Full-Length ERK2 Substrate AlphaLISA Technology Author: Jeanine Hinterneder, PhD PerkinElmer, Inc. Hopkinton, MA Introduction The mitogen-activated
More informationFinancial Results FY2018 Q3
Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs
More informationSUPPLEMENTAL FIGURE LEGENDS. Figure S1: Homology alignment of DDR2 amino acid sequence. Shown are
SUPPLEMENTAL FIGURE LEGENDS Figure S1: Homology alignment of DDR2 amino acid sequence. Shown are the amino acid sequences of human DDR2, mouse DDR2 and the closest homologs in zebrafish and C. Elegans.
More informationCell Health and Viability Assays Real-time automated measurements of cell health and viability inside your incubator
INCUCYTE LIVE-CELL ANALYSIS SYSTEM Cell Health and Viability Assays Real-time automated measurements of cell health and viability inside your incubator See what your cells are doing and when they do it
More informationZ -LYTE KINASE ASSAY KIT TYR 3 PEPTIDE PROTOCOL
Z -LYTE KINASE ASSAY KIT TYR 3 PEPTIDE PROTOCOL Cat. no. PV3192 O-062193-r1 US 0405 TABLE OF CONTENTS 1.0 INTRODUCTION... 2 2.0 ASSAY THEORY... 2 3.0 Z9-LYTE KINASE ASSAY KIT TYR 3 PEPTIDE MATERIALS PROVIDED...
More informationIncyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs
Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs November 1, 2016 $224 million of 2016 third-quarter net product revenues from Jakafi (ruxolitinib), representing 39
More informationInvestigating Compound Mechanism of Action
Investigating Compound Mechanism of Action Using Genetic Interaction Screens Lisa Marshall, Priya Mitty, Michael Ollmann, and Paul Kassner Michael Ollmann, Ph.D. Principal Scientist, Therapeutic Discovery
More informationKREX World s only proteomics technology that produces full-length, correctly folded, functionally verified proteins
THE functional proteomics company KREX World s only proteomics technology that produces full-length, correctly folded, functionally verified proteins SENGENICS IS A CAMBRIDGE UNIVERSITY SPIN-OFF COMPANY
More informationPaul Bowyer. (Baker Lab, London School of Hygiene and Tropical Medicine)
Evaluation of selective inhibitors of the malarial cyclic GMP dependent protein kinase (PKG) Paul Bowyer (Baker Lab, London School of Hygiene and Tropical Medicine) Talk summary An overview of the P. falciparum
More informationENCePP Plenary meeting 12 November
ENCePP Plenary meeting 12 November Introduction to Pharmacogenomics Presented by: Marisa Papaluca Head of Scientific Support Office European Medicines Agency An agency of the European Union Pharmacogenomics
More informationApril transmart v1.2 Case Study for PredicTox
April 2015 transmart v1.2 Case Study for PredicTox Agenda Agenda! What is PredicTox?! Brief transmart overview! Answering scientific questions with transmart s help: A case study maximizing data value!
More informationQS S Assist KINASE_MSA Kit
QS S Assist KINASE_MSA Kit Description KINASE MSA Kit is designed for use in pharmacological assays for KINASE based on Off-chip mobility shift assay (MSA). This kit includes Assay Buffer, Termination
More informationAn Automated, Cell-based Platform for the Rapid Detection of Novel Androgen Receptor Modulators
A p p l i c a t i o n N o t e An Automated, Cell-based Platform for the Rapid Detection of Novel Androgen Receptor Modulators Brad Larson and Peter Banks, BioTek Instruments, Inc., Winooski, VT Bruce Sherf,
More informationExploring Protein Phosphorylation with RayBio Antibody Arrays and ELISAs
Exploring Protein Phosphorylation with RayBio Antibody Arrays and ELISAs Valerie Sloane Jones, Ph.D.* 1, Hao Tang, Ph.D. 1, Ruo-Pan Huang, M.D., Ph.D. 1,2 1 RayBiotech, Inc., 3607 Parkway Lane, Suite 100,
More informationCombining Target-Based and Phenotypic Discovery Assays for Drug Repurposing. Sharlene Velichko, Ph.D. Director of Research Biology November 11, 2017
Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing Sharlene Velichko, Ph.D. Director of Research Biology November 11, 2017 1 Drug Repurposing Finding new life for old drugs Initial
More informationMiniaturized Whole Cell-based GPCR camp Assay Using a Novel Detection System
Miniaturized Whole Cell-based GPCR camp Assay Using a Novel Detection System Geetha Shankar, Ph.D. Associate Director New Lead Discovery Exelixis, Inc South San Francisco, CA Overview GPCR HTS assays ACT:One
More informationFast, Sensitive Detection of EGF-Induced Receptor Autophosphorylation in Cell Lysates
Fast, Sensitive Detection of EGF-Induced Receptor Paula Denney Eason, Rachel A. Saxer, Robert M. Umek, James L. Wilbur, George B. Sigal, Eli N. Glezer, Hans A. Biebuyck, and Jacob N. Wohlstadter Abstract
More informationPIPETMAX : Flexible Automated Workflow for Kinase Selectivity Profiling
PIPETMAX : Flexible Automated Workflow for Kinase Selectivity Profiling APPLICATION NOTE AN1002 APPLICATION BENEFITS Reliable and reproducible methods for screening kinase inhibitors are an important part
More informationClinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Kymriah) Reference Number: CP.CPA.XX Effective Date: 09.26.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationFlow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity
Flow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity Michele Romano, PhD Product Manager Flow CAST is for Research Use Only. Not for use in diagnostic procedures.
More informationSystem. Dynamic Monitoring of Receptor Tyrosine Kinase Activation in Living Cells. Application Note No. 4 / March
System Application Note No. 4 / March 2008 Dynamic Monitoring of Receptor Tyrosine Kinase Activation in Living Cells www.roche-applied-science.com Dynamic Monitoring of Receptor Tyrosine Kinase Activation
More informationFRAUNHOFER IME SCREENINGPORT
FRAUNHOFER IME SCREENINGPORT Detection technologies used in drug discovery Introduction Detection technologies in drug discovery is unlimited only a biased snapshot can be presented Differences can presented
More informationChagas Disease Drug Discovery Entering a New Era. Eric Chatelain, PhD Head of Drug Discovery
Chagas Disease Drug Discovery Entering a New Era Eric Chatelain, PhD Head of Drug Discovery ICOPA Meeting, Mexico, 12 th August 2014 Chagas Disease Effective immune responses provide control of the infection
More informationData Sheet. TDO Cell-Based Assay Kit Catalog #72033
Data Sheet TDO Cell-Based Assay Kit Catalog #72033 6044 Cornerstone Court W, Ste E Background L-tryptophan (L-Trp) is an essential amino acid necessary for protein synthesis in mammalian cells and the
More informationCompound Re-Profiling. Dr Robert Scoffin CEO, Cresset
Compound Re-Profiling Dr Robert Scoffin CEO, Cresset What is it? F F F N N H 2 N S O O Br > Compound Re-Profiling or Re-Purposing is the process of finding a new clinical use for an existing treatment
More informationOptimization of an Adapta Kinase Assay for Cdk9/cyclin T1
Optimization of an Adapta Kinase Assay for Cdk9/cyclin T1 Overview This protocol describes how to perform an Adapta assay with the kinase Cdk9/cyclin T1. To maximize the ability of the assay to detect
More informationDrug Discovery Pipeline Overview 2011
Guangzhou Institutes of Drug Discovery Pipeline Overview 2011 1 Goal of the Pipeline Guangzhou Institutes of Mission: Capture the best ideas from the 3 scientific institutes at GIBH and translate the ideas
More informationParallel analysis of translated ORF (PLATO)
Parallel analysis of translated ORF (PLATO) Technical Journal Club 16.04.2013 Mary-Aude Rochat, PhD student Speck group Proteomics Rationale: Increase in the DNA sequence information Understand biological
More informationUse of a Label-Free Platform in a preclinical Contract Research Organization Environment
Use of a Label-Free Platform in a preclinical Contract Research Organization Environment Scott Perschke Director, Assay Development Contents Introduction 2 Problem Statement 2 Previous Options 2 Solution
More informationPolypharmacology. Giulio Rastelli Molecular Modelling and Drug Design Lab
Polypharmacology Giulio Rastelli Molecular Modelling and Drug Design Lab www.mmddlab.unimore.it Dipartimento di Scienze della Vita Università di Modena e Reggio Emilia giulio.rastelli@unimore.it Magic
More informationComparison of LANCE Ultra TR-FRET to PerkinElmer s Classical LANCE TR-FRET Platform for Kinase Applications
Comparison of LANCE Ultra TR-FRET to PerkinElmer s Classical LANCE TR-FRET Platform for Kinase Applications LANCE ULTRA TR-FRET TECHNOLOGY A P P L I C A T I O N N O T E Introduction Protein kinases play
More informationProtein kinases catalyze the transfer of the gammaphosphate
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. pubs.acs.org/acschemicalbiology
More informationSynthesis of the pyridinyl analogues of dibenzylideneacetone. (pyr-dba) via an improved Claisen-Schmidt condensation,
Synthesis of the pyridinyl analogues of dibenzylideneacetone (pyr-dba) via an improved Claisen-Schmidt condensation, displaying diverse biological activities as curcumin analogues Bin Cao, Yong Wang, Kan
More informationMETABOLIC PROFILING AND SIGNATURES IN ALS. Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina
METABOLIC PROFILING AND SIGNATURES IN ALS Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina Metabolomics is the newest Omics science DNA Genomics RNA Transcriptomics
More informationSharing Regulatory Intelligence: Best Practices and Case Studies
Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationTargeting Proteins for Degradation: Characterizing PROTAC Kinetics and Mode of Action using Live-Cell Assays. Kristin M. Riching, Ph.
Targeting Proteins for Degradation: Characterizing PROTAC Kinetics and Mode of Action using Live-Cell Assays Kristin M. Riching, Ph.D PROTACs: An Attractive Drug Discovery Strategy PROTACs, or Proteolysis
More informationThe use of target immobilised NMR screening to identify and develop fragment binders to Hsp90
The use of target immobilised MR screening to identify and develop fragment binders to sp90 ot topics in drug discovery: finding the next lead 11 ovember 2009 John Porter 2009 UCB Celltech Introduction
More informationZ -LYTE fluorescent kinase assay technology. Z -LYTE Kinase Assay Platform
Z -LYTE fluorescent kinase assay technology Z -LYTE Kinase Assay Platform Z -LYTE Kinase Assay Platform Non-radioactive assay format for screening a diverse collection of over 185 kinase targets Assay
More informationCompound-Target Engagement Cell-Based Assays. Assays, Validation, and Publications
Compound-Target Engagement Cell-Based Assays Assays, Validation, and Publications 1 Agenda What is Compound-Target Engagement? Cell-Based Target Engagement Assays Customer needs Products and services Assay
More informationSureSilencing sirna Array Technology Overview
SureSilencing sirna Array Technology Overview Pathway-Focused sirna-based RNA Interference Topics to be Covered Who is SuperArray? Brief Introduction to RNA Interference Challenges Facing RNA Interference
More informationThe Changing Paradigm of Tropical Medicine: The Role of TropMed Mahidol
Discussion on To be a World Leader in Tropical Medicine Faculty of Tropical Medicine, Mahidol University, 29 May 2015 The Changing Paradigm of Tropical Medicine: The Role of TropMed Mahidol Yongyuth Yuthavong
More informationFragment-based screening of enzyme drug targets: Microfluidic mobility shift assay improves confidence in candidate selection
Fragment-based screening of enzyme drug targets: Microfluidic mobility shift assay improves confidence in candidate selection Introduction Fragment-based lead discovery is establishing itself as valuable
More informationThe Kinase Knowledgebase
The Kinase Knowledgebase Kevin P. Hambly Product Manager Derek A. Debe, Ph.D. Chief Scientific Officer Outline About Eidogen-Sertanty Kinase Knowledgebase Overview Content Curation Process Data Structure
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/6/304/ra104/dc1 Supplementary Materials for Lysine Methylation Promotes VEGFR-2 Activation and Angiogenesis Edward J. Hartsough, Rosana D. Meyer, Vipul Chitalia,
More informationSensoLyte AMC Calpain Activity Assay Kit *Fluorimetric*
SensoLyte AMC Calpain Activity Assay Kit *Fluorimetric* Catalog # 72150 Kit Size 100 Assays (96-well plate) Optimized Performance: This kit is optimized to detect calpain activity Enhanced Value: It provides
More informationSensoLyte Homogeneous AFC Caspase-8 Assay Kit *Fluorimetric*
SensoLyte Homogeneous AFC Caspase-8 Assay Kit *Fluorimetric* Catalog # 72088-100 Kit Size 100 Assays (96-well plate) Optimized Performance: This kit is optimized to detect caspase-8 activity. Enhanced
More informationZ -LYTE KINASE ASSAY KIT SER/THR 9 PEPTIDE PROTOCOL
Z -LYTE KINASE ASSAY KIT SER/THR 9 PEPTIDE PROTOCOL Part # PV3324 Lit. # 762-038412 020304 TABLE OF CONTENTS 1.0 INTRODUCTION... 2 2.0 ASSAY THEORY... 2 3.0 Z -LYTE KINASE ASSAY KIT SER/THR 9 PEPTIDE MATERIALS
More informationHow To Choose a GeneCopoeia Luciferase System. Ed Davis, Ph.D.
TECHNICAL NOTE How To Choose a GeneCopoeia Luciferase System Ed Davis, Ph.D. Introduction Luciferase reporter systems are invaluable tools for several applications, including regulation of gene expression
More informationHighly selective MERTK inhibitors achieved by a single methyl group
Highly selective MERTK inhibitors achieved by a single methyl group Jichen Zhao, ± Dehui Zhang, ±, Weihe Zhang, ± Michael A. Stashko, ± Deborah DeRyckere, Eleana Vasileiadi, Rebecca E. Parker, Debra Hunter,
More informationUse of Echo Liquid Handlers to Improve the Efficiency and Reliability of Bioassay Laboratories
Use of Echo Liquid Handlers to Improve the Efficiency and Reliability of Bioassay Laboratories Tim Allison, May 8, 2017 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, the Labcyte logo are registered
More informationMicroRNA Analysis Paired with Novel Cell Health Assays: A Complete Workflow
MicroRNA Analysis Paired with Novel Cell Health Assays: A Complete Workflow Brad Hook, Ph.D Manager, NA Scientific Applications 2016 Presentation Outline From cells to RNA a seemingly easy, yet complex
More information5.36 Biochemistry Laboratory Spring 2009
MIT OpenCourseWare http://ocw.mit.edu 5.36 Biochemistry Laboratory Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. SESSION 13 and SESSION
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0419 TITLE: Development of Specific Inhibitors for Breast Cancer-Associated Variants of ErbB2 PRINCIPAL INVESTIGATOR: W. Todd Miller CONTRACTING ORGANIZATION: The Research Foundation
More informationData Sheet. SBE Reporter Kit (TGFβ/SMAD signaling pathway) Catalog #: 60654
Data Sheet SBE Reporter Kit (TGFβ/SMAD signaling pathway) Catalog #: 60654 Background The transforming growth factor beta (TGFβ) signaling pathway is involved in a diverse range of cell processes such
More informationCHAPTER 4. Milestones of the drug discovery
CHAPTER 4 Milestones of the drug discovery 4.Milestones of the drug discovery: Highlights the importance of the below critical milestones of the drug discovery and correlated to the current research. 1.
More informationTanja Krainz Current Literature July 9 th, 2016
Discovery and Characterization of BMN673 (Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1,2 Inhibitor, as an Anticancer Agent Wang, B.; Chu, D.; Feng, Y.; Shen,
More informationInhibitors of Mycobacterium tuberculosis DosRST signaling and persistence
Supplementary Information Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence uiqing Zheng 1, Christopher J. Colvin 1, Benjamin K. Johnson 1, Paul D. Kirchhoff 2, Michael Wilson 2,
More informationOptimization of a LanthaScreen Kinase assay for BRAF V599E
Optimization of a LanthaScreen Kinase assay for BRAF V599E Overview This protocol describes how to develop a LanthaScreen kinase assay designed to detect and characterize inhibitors of BRAF V599E using
More informationPD-1 Pathway Recombinant Protein Collection
Pathway Recombinant Protein Collection www.acrobiosystems.com Content I. Introduction II. Biotinylated Pathway Proteins IIa. ELISA IIb. FAC Sorting IIc. Biopanning III. HPLC-verified Proteins IV. Full-length
More informationPolarScreen Tyrosine Kinase Assay Kit, Far Red Protocol
PolarScreen Tyrosine Kinase Assay Kit, Far Red Protocol Part # PV3327 Lit. # 839-0408647 040804 TABLE OF CONTENTS 1.0 INTRODUCTION... 1 2.0 ASSAY THEORY... 2 3.0 KIT COMPONENTS... 3 3.1 Materials Provided...
More informationLabcyte Overview. Mark Fischer-Colbrie
MOVING LIQUIDS with SOUND Labcyte Overview Mark Fischer-Colbrie 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, the Labcyte logo are registered trademarks or trademarks of Labcyte Inc., in the U.S.
More informationThe Transfection Collection TCF/LEF Transient Pack Wnt / -catenin Signaling Pathway Catalog #: 79273
Data Sheet The Transfection Collection TCF/LEF Transient Pack Wnt / -catenin Signaling Pathway Catalog #: 79273 Background The Wnt / -catenin signaling pathway controls a large and diverse set of cell
More informationFlashPlate File #13. A Homogeneous Protein Kinase Assay Performed on 384-Well Streptavidin-Coated FlashPlate HTS PLUS. High Throughput Screening
Drug Discovery Research Clinical Screening High Throughput Screening FlashPlate File #13 A Homogeneous Protein Kinase Assay Performed on 384-Well Streptavidin-Coated FlashPlate HTS PLUS Carol Geist, Sally
More informationOncoMD User Manual Version 2.6. OncoMD: Cancer Analytics Platform
OncoMD: Cancer Analytics Platform 1 Table of Contents 1. INTRODUCTION... 3 2. OVERVIEW OF ONCOMD... 3 3. ORGANIZATION OF INFORMATION IN ONCOMD... 3 4. GETTING STARTED... 6 4.1 USER AUTHENTICATION... 6
More informationPersonalized CAR-T Immunotherapy Platform
GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom
More informationData Sheet. CRE/CREB Reporter Assay Kit (camp/pka Cell Signaling Pathway) Catalog #: 60611
Data Sheet CRE/CREB Reporter Assay Kit (camp/pka Cell Signaling Pathway) Catalog #: 60611 Background The main role of the camp response element, or CRE, is mediating the effects of Protein Kinase A (PKA)
More informationGα i Activation Assay Kit
A helping hand for your research Product Manual Configuration-specific Monoclonal Antibody Based Gα i Activation Assay Kit Catalog Number 80301 20 assays NewEast Biosciences, Inc 1 Table of Content Product
More informationHossain_Supplemental Figure 1
Hossain_Supplemental Figure 1 GFP-PACT GFP-PACT Motif I GFP-PACT Motif II A. MG132 (1µM) GFP Tubulin GFP-PACT Pericentrin GFP-PACT GFP-PACT Pericentrin Fig. S1. Expression and localization of Orc1 PACT
More informationThe Open Pharmacological Concepts Triple Store
The Open Pharmacological Concepts Triple Store Gerhard F. Ecker Dept Medicinal Chemistry, Univ Vienna Gerhard.f.ecker@univie.ac.at; www.openphacts.org The Innovative Medicines Initiative EC funded public-private
More informationMolecular & Cellular Proteomics 8: , 2009.
Felix S. Oppermann, Florian Gnad, Jesper V. Olsen, Renate Hornberger, Zolta n Greff, Gyorgy Keri, Matthias Mann, and Henrik Daub. Molecular & Cellular Proteomics 8:1751 1764, 2009. Presented by Yi-Ting
More informationPreclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator
S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra
More informationME-401: A Highly Differentiated PI3Kd- Selective Inhibitor
NASDAQ: MEIP ME-401: A Highly Differentiated PI3Kd- Selective Inhibitor June 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual
More informationPerforming Bioenergetic Analysis:
icell Neurons Application Protocol Performing Bioenergetic Analysis: XF96 Extracellular Flux Analyzer Introduction Neurons are highly metabolic cells that heavily depend on mitochondrial function for cell
More informationKinase Activity: a total solution
Kinase Activity: a total solution Protein arrays for multiplex kinetic measurements Robust Instrumentation User friendly software Kinetic data at your fingertips! PamGene s novel platform for profiling
More informationGeneration of research tools to translate genomic discoveries into drug discovery projects. Nils Ostermann, Novartis
Generation of research tools to translate genomic discoveries into drug discovery projects Nils Ostermann, Novartis Need for public-private collaboration Common interest Genomic information is growing
More informationFollowing text taken from Suresh Kumar. Bioinformatics Web - Comprehensive educational resource on Bioinformatics. 6th May.2005
Bioinformatics is the recording, annotation, storage, analysis, and searching/retrieval of nucleic acid sequence (genes and RNAs), protein sequence and structural information. This includes databases of
More informationEnterprise Interest I am an employee of ThermoFisher Scientific.
Enterprise Interest I am an employee of ThermoFisher Scientific. Developing a multiplex next-generation sequencing assay to study highly clonal tumor samples Dumitru Brinza, Ph.D Clinical Next-Generation
More informationTITLE: Elucidating Mechanisms of Farnesyltransferase Inhibitor Action and Resistance in Breast Cancer by Bioluminescence Imaging
AD Award Number: W81XWH-07-1-0426 TITLE: Elucidating Mechanisms of Farnesyltransferase Inhibitor Action and Resistance in Breast Cancer by Bioluminescence Imaging PRINCIPAL INVESTIGATOR: David Piwnica-Worms,
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationPharmaceutical Informatics and the Pathway to Personalized Medicines
Pharmaceutical Informatics and the Pathway to Personalized Medicines Sangtae Kim and Venkat Venkatasubramanian Purdue University ICCS2007 DDDAS Workshop Beijing May 26-28, 2007 Outline The Grand Challenge
More informationDevelopment and Utilization of Bromodomain and Extra Terminal Domain (BET) Assays Using AlphaLISA Technology
APPLICATION NOTE AlphaLISA Technology Authors: Hong Cao Daniel Cardillo Jen Carlstrom Dawn Nida PerkinElmer, Inc. Hopkinton, MA Development and Utilization of Bromodomain and Extra Terminal Domain (BET)
More informationPhoreMost Ltd. Phenotypic screening for novel druggable targets using Protein-interference
PhoreMost Ltd Phenotypic screening for novel druggable targets using Protein-interference Company Snap-shot PhoreMost Ltd: New Biotech with a mission to drug key underlying causes of unmet diseases, the
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationpt7ht vector and over-expressed in E. coli as inclusion bodies. Cells were lysed in 6 M
Supplementary Methods MIG6 production, purification, inhibition, and kinase assays MIG6 segment 1 (30mer, residues 334 364) peptide was synthesized using standard solid-phase peptide synthesis as described
More informationData Sheet. TCF/LEF Reporter Kit Wnt / -catenin signaling pathway Catalog #: 60500
Data Sheet TCF/LEF Reporter Kit Wnt / -catenin signaling pathway Catalog #: 60500 Background The Wnt / -catenin signaling pathway controls a large and diverse set of cell fate decisions in embryonic development,
More informationCurrent Guidelines for Drug-drug Interaction Evaluation
Current Guidelines for Drug-drug Interaction Evaluation Odette A Fahmi, PhD DDI-Edge Consulting, LLC June 2018 21 ST International Conference on Drug-Drug Interactions OUTLINE Recommended DDI approaches
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationFinancial Results FY2017
Financial Results FY2017 (January to December 2017) Carna Biosciences, Inc. Stock Code:4572 1 Building a Sustainable Company Continuously Discovering and Delivering Innovative Therapies for Patients by
More information